Relationship of plasma renin with a prothrombotic state in hypertension: Relevance for organ damage

American Journal of Hypertension

Volumn 21, Issue 12, 2008, Pages 1347-1353

  Sechi, Leonardo A ^a   Novello, Marileda ^a   Colussi, Gianluca ^a   Di Fabio, Alessandro ^a   Chiuch, Alessandra ^a   Nadalini, Elisa ^a   Casanova Borca, Alessia ^a   Uzzau, Alessandro ^a   Catena, Cristiana ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART INJURY; HEMOSTASIS; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; ORGAN INJURY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ALDOSTERONE; ALGORITHMS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HEART DISEASES; HUMANS; HYPERTENSION; ITALY; KIDNEY DISEASES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; REGRESSION ANALYSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SERINE PROTEINASE INHIBITORS;

EID: 56549090663     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.293     Document Type: Article

References (40)

1. MacMahon S, Peto R, Cutler J, Collin R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease. Part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
2. Brunner HR, Laragh JH, Bear L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286:441-449.
3. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
4. Blood Pressure Lowering. Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951-958.
5. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366:2026-2033.
6. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001; 87(suppl):10C-17C.
7. Lip GY. Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or "Birmingham paradox") revisited. Hypertension 2003; 41: 199-200.
8. Rabbani LE, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of atherothrombotic plaques. Atherosclerosis 1994; 104:1-7.
9. Sechi LA, Zingaro L, Catena C, Casaccio D, De Marchi S. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000; 36:978-985.
10. Lip GY, Blann AD. Does hypertension confer a hypercoagulable state? Vircow's triad revisited. Circulation 2000; 101:218-220.
11. Lip GY. Target organ damage and the prothrombotic state in hypertension. Hypertension 2000; 36:975-977.
12. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45:419-429.
13. Felmeden DC, Lip GY. The renin-angiotensin-aldosterone system and fibrinolysis. J Renin Angiotensin Aldosterone Syst 2000; 1:240-244.
14. Dielis AWJH, Smid M, Spronk HMH, Hamulyak K, Kroon AA, ten Cate H, de Leeuw PW. The prothrombotic paradox of hypertension. Role of the renin-angiotensin and kallicrein-kinin system. Hypertension 2005; 46:1236-1242.
15. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32:965-971.
16. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34:285-290.
17. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002; 40:859-865.
18. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Des 2003; 9:1715-1732.
19. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 2003; 88:3867-3873.
20. Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension 2005; 46:313-320.
21. Fogari R, Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006; 19:1293-1299.
22. Brown NJ, Muldowney JA, Vaughan DE. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Hypertension 2006; 47:441-448.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
24. Grafnetter D, Feruglio GA, Vanuzzo D. Standardization of methods of lipid determination according to WHO in the regional project of prevention of cardiovascular diseases in Friuli-Venezia Giulia. G Ital Cardiol 1996; 26:287-297.
25. Krobot K, Heuse HW, Cremer P, Eberle E, Kil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age and sex: results from the second MONICA Augsburg Survey 1989-90. Arterioscler Thromb 1992; 12:780-788.
26. Folsom AR, Qamhieh HT, Flack JM for the investigators of the coronary artery risk development in young adults (CARDIA) study. Plasma fibrinogen levels and correlated in young adults. Am J Epidemiol 1993; 138:1023-1026.
27. Sechi LA, Zingaro L, Catena C, De Marchi S. Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events. Thromb Haemost 2000; 84:565-570.
28. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E. Association of lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 1997; 277:1689-1695.
29. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85.
30. Soardo G, Donnini D, Varutti R, Moretti M, Milocco C, Basan L, Esposito W, Casaccio D, Stel G, Catena C, Curcio F, Sechi LA. Alcohol-induced endothelial changes are associated with oxidative stress and are rapidly reversed after withdrawal. Alcohol Clin Exp Res 2005; 29:1889-1898.
31. Sealey JE, Gordon RD, Mantero F. Plasma renin and aldosterone measurements in low-renin hypertensive states. Trends Endocrinol Metab 2005; 16:86-91.
32. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007; 2:722-731.
33. Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. Am J Hypertens 2002; 15:683-690.
34. Vaughan DE, Lazos S, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995-1001.
35. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT. Aldosterone plasys a pivotal role in the pathogenensis ofthrombotic microangiopathy in SHRSP. J Am Soc Nephrol 2003; 14:1990-1997.
36. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
37. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotenisn II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85:336-344.
38. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002; 87:448-452.
39. Chun T-Y, Chander PN, Kim J-W, Pratt H, Stier CT. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am J Physiol 2008; 295:E305-E312.
40. Catena C, Novello M, Lapenna R, Baroselli S, Colussi G, Nadalini E, Favret G, Cavarape A, Soardo G, Sechi LA. New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a). J Hypertens 2005; 23: 1617-1631.